25 XP   0   0   10

Nykode Therapeutics ASA
Buy, Hold or Sell?

Let's analyse Nykode together

PenkeI guess you are interested in Nykode Therapeutics ASA. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Nykode Therapeutics ASA. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Nykode Therapeutics ASA

I send you an email if I find something interesting about Nykode Therapeutics ASA.

Quick analysis of Nykode (30 sec.)










What can you expect buying and holding a share of Nykode? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr5.31
Expected worth in 1 year
kr0.30
How sure are you?
57.1%

+ What do you gain per year?

Total Gains per Share
kr-5.01
Return On Investment
-39.9%

For what price can you sell your share?

Current Price per Share
kr12.54
Expected price per share
kr0 - kr16.78
How sure are you?
50%

1. Valuation of Nykode (5 min.)




Live pricePrice per Share (EOD)

kr12.54

Intrinsic Value Per Share

kr7.51 - kr8.41

Total Value Per Share

kr12.82 - kr13.72

2. Growth of Nykode (5 min.)




Is Nykode growing?

Current yearPrevious yearGrowGrow %
How rich?$157m$194.1m-$37m-23.6%

How much money is Nykode making?

Current yearPrevious yearGrowGrow %
Making money-$42.7m-$9.4m-$33.3m-78.0%
Net Profit Margin-596.3%-27.7%--

How much money comes from the company's main activities?

3. Financial Health of Nykode (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#296 / 1016

Most Revenue
#329 / 1016

Most Profit
#868 / 1016

Most Efficient
#769 / 1016

What can you expect buying and holding a share of Nykode? (5 min.)

Welcome investor! Nykode's management wants to use your money to grow the business. In return you get a share of Nykode.

What can you expect buying and holding a share of Nykode?

First you should know what it really means to hold a share of Nykode. And how you can make/lose money.

Speculation

The Price per Share of Nykode is kr12.54. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Nykode.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Nykode, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr5.31. Based on the TTM, the Book Value Change Per Share is kr-1.25 per quarter. Based on the YOY, the Book Value Change Per Share is kr0.51 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Nykode.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps-0.13-1.0%-0.13-1.0%-0.03-0.2%0.010.1%-0.010.0%
Usd Book Value Change Per Share-0.11-0.9%-0.11-0.9%0.050.4%0.080.7%0.070.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.11-0.9%-0.11-0.9%0.050.4%0.080.7%0.070.5%
Usd Price Per Share2.55-2.55-7.31-3.33-2.38-
Price to Earnings Ratio-19.46--19.46--253.52--51.63--36.88-
Price-to-Total Gains Ratio-22.45--22.45-156.96-49.72-49.72-
Price to Book Ratio5.30-5.30-12.30-6.00-4.28-
Price-to-Total Gains Ratio-22.45--22.45-156.96-49.72-49.72-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.136124
Number of shares880
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.110.08
Usd Total Gains Per Share-0.110.08
Gains per Quarter (880 shares)-99.8572.45
Gains per Year (880 shares)-399.39289.79
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-399-4090290280
20-799-8080580570
30-1198-12070869860
40-1598-1606011591150
50-1997-2005014491440
60-2396-2404017391730
70-2796-2803020292020
80-3195-3202023182310
90-3595-3601026082600
100-3994-4000028982890

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%1.06.00.014.3%1.06.00.014.3%
Book Value Change Per Share0.01.00.00.0%2.01.00.066.7%3.02.00.060.0%4.03.00.057.1%4.03.00.057.1%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.07.00.0%0.00.07.00.0%
Total Gains per Share0.01.00.00.0%2.01.00.066.7%3.02.00.060.0%4.03.00.057.1%4.03.00.057.1%

Fundamentals of Nykode

About Nykode Therapeutics ASA

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for COVID-19 T cell vaccine development; and research agreement with Regeneron. The company was formerly known as Vaccibody AS. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.

Fundamental data was last updated by Penke on 2024-03-29 23:30:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Nykode Therapeutics ASA.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Nykode earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Nykode to the Biotechnology industry mean.
  • A Net Profit Margin of -596.3% means that kr-5.96 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Nykode Therapeutics ASA:

  • The MRQ is -596.3%. The company is making a huge loss. -2
  • The TTM is -596.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-596.3%TTM-596.3%0.0%
TTM-596.3%YOY-27.7%-568.6%
TTM-596.3%5Y-14,954.4%+14,358.1%
5Y-14,954.4%10Y-12,557.0%-2,397.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-596.3%-197.2%-399.1%
TTM-596.3%-210.4%-385.9%
YOY-27.7%-279.3%+251.6%
5Y-14,954.4%-436.8%-14,517.6%
10Y-12,557.0%-599.3%-11,957.7%
1.1.2. Return on Assets

Shows how efficient Nykode is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Nykode to the Biotechnology industry mean.
  • -19.3% Return on Assets means that Nykode generated kr-0.19 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Nykode Therapeutics ASA:

  • The MRQ is -19.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -19.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-19.3%TTM-19.3%0.0%
TTM-19.3%YOY-3.5%-15.8%
TTM-19.3%5Y-8.1%-11.2%
5Y-8.1%10Y-8.8%+0.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-19.3%-13.6%-5.7%
TTM-19.3%-12.9%-6.4%
YOY-3.5%-11.9%+8.4%
5Y-8.1%-14.2%+6.1%
10Y-8.8%-16.2%+7.4%
1.1.3. Return on Equity

Shows how efficient Nykode is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Nykode to the Biotechnology industry mean.
  • -27.2% Return on Equity means Nykode generated kr-0.27 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Nykode Therapeutics ASA:

  • The MRQ is -27.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -27.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-27.2%TTM-27.2%0.0%
TTM-27.2%YOY-4.9%-22.4%
TTM-27.2%5Y-8.7%-18.5%
5Y-8.7%10Y-9.4%+0.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-27.2%-17.0%-10.2%
TTM-27.2%-16.1%-11.1%
YOY-4.9%-15.4%+10.5%
5Y-8.7%-20.0%+11.3%
10Y-9.4%-21.1%+11.7%

1.2. Operating Efficiency of Nykode Therapeutics ASA.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Nykode is operating .

  • Measures how much profit Nykode makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Nykode to the Biotechnology industry mean.
  • An Operating Margin of -741.6% means the company generated kr-7.42  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Nykode Therapeutics ASA:

  • The MRQ is -741.6%. The company is operating very inefficient. -2
  • The TTM is -741.6%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-741.6%TTM-741.6%0.0%
TTM-741.6%YOY-31.7%-709.8%
TTM-741.6%5Y-96,996.5%+96,254.9%
5Y-96,996.5%10Y-78,251.0%-18,745.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-741.6%-286.1%-455.5%
TTM-741.6%-224.4%-517.2%
YOY-31.7%-288.4%+256.7%
5Y-96,996.5%-475.2%-96,521.3%
10Y-78,251.0%-624.7%-77,626.3%
1.2.2. Operating Ratio

Measures how efficient Nykode is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 8.47 means that the operating costs are kr8.47 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Nykode Therapeutics ASA:

  • The MRQ is 8.471. The company is inefficient in keeping operating costs low. -1
  • The TTM is 8.471. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ8.471TTM8.4710.000
TTM8.471YOY1.317+7.154
TTM8.4715Y148.245-139.774
5Y148.24510Y105.890+42.356
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.4712.997+5.474
TTM8.4713.247+5.224
YOY1.3173.766-2.449
5Y148.2455.675+142.570
10Y105.8907.857+98.033

1.3. Liquidity of Nykode Therapeutics ASA.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Nykode is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.43 means the company has kr5.43 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Nykode Therapeutics ASA:

  • The MRQ is 5.435. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.435. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.435TTM5.4350.000
TTM5.435YOY8.157-2.722
TTM5.4355Y10.035-4.600
5Y10.03510Y12.005-1.970
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.4353.930+1.505
TTM5.4354.251+1.184
YOY8.1575.436+2.721
5Y10.0356.045+3.990
10Y12.0056.363+5.642
1.3.2. Quick Ratio

Measures if Nykode is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Nykode to the Biotechnology industry mean.
  • A Quick Ratio of 5.35 means the company can pay off kr5.35 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Nykode Therapeutics ASA:

  • The MRQ is 5.345. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 5.345. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.345TTM5.3450.000
TTM5.345YOY8.427-3.081
TTM5.3455Y9.431-4.086
5Y9.43110Y7.573+1.858
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.3453.629+1.716
TTM5.3454.065+1.280
YOY8.4275.397+3.030
5Y9.4315.993+3.438
10Y7.5736.277+1.296

1.4. Solvency of Nykode Therapeutics ASA.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Nykode assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Nykode to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.29 means that Nykode assets are financed with 29.1% credit (debt) and the remaining percentage (100% - 29.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Nykode Therapeutics ASA:

  • The MRQ is 0.291. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.291. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.291TTM0.2910.000
TTM0.291YOY0.269+0.022
TTM0.2915Y0.208+0.083
5Y0.20810Y0.166+0.042
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2910.332-0.041
TTM0.2910.334-0.043
YOY0.2690.268+0.001
5Y0.2080.366-0.158
10Y0.1660.390-0.224
1.4.2. Debt to Equity Ratio

Measures if Nykode is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Nykode to the Biotechnology industry mean.
  • A Debt to Equity ratio of 41.1% means that company has kr0.41 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Nykode Therapeutics ASA:

  • The MRQ is 0.411. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.411. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.411TTM0.4110.000
TTM0.411YOY0.368+0.042
TTM0.4115Y0.274+0.137
5Y0.27410Y0.214+0.060
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4110.381+0.030
TTM0.4110.390+0.021
YOY0.3680.334+0.034
5Y0.2740.434-0.160
10Y0.2140.466-0.252

2. Market Valuation of Nykode Therapeutics ASA

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Nykode generates.

  • Above 15 is considered overpriced but always compare Nykode to the Biotechnology industry mean.
  • A PE ratio of -19.46 means the investor is paying kr-19.46 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Nykode Therapeutics ASA:

  • The EOD is -8.676. Based on the earnings, the company is expensive. -2
  • The MRQ is -19.456. Based on the earnings, the company is expensive. -2
  • The TTM is -19.456. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.676MRQ-19.456+10.780
MRQ-19.456TTM-19.4560.000
TTM-19.456YOY-253.517+234.061
TTM-19.4565Y-51.633+32.177
5Y-51.63310Y-36.881-14.752
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-8.676-2.315-6.361
MRQ-19.456-2.560-16.896
TTM-19.456-2.664-16.792
YOY-253.517-4.122-249.395
5Y-51.633-6.258-45.375
10Y-36.881-6.108-30.773
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Nykode Therapeutics ASA:

  • The EOD is -15.870. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -35.588. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -35.588. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-15.870MRQ-35.588+19.718
MRQ-35.588TTM-35.5880.000
TTM-35.588YOY8,403.566-8,439.154
TTM-35.5885Y1,676.057-1,711.645
5Y1,676.05710Y1,197.184+478.874
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-15.870-3.067-12.803
MRQ-35.588-3.251-32.337
TTM-35.588-3.545-32.043
YOY8,403.566-5.595+8,409.161
5Y1,676.057-8.315+1,684.372
10Y1,197.184-8.708+1,205.892
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Nykode is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 5.30 means the investor is paying kr5.30 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Nykode Therapeutics ASA:

  • The EOD is 2.362. Based on the equity, the company is underpriced. +1
  • The MRQ is 5.296. Based on the equity, the company is overpriced. -1
  • The TTM is 5.296. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD2.362MRQ5.296-2.934
MRQ5.296TTM5.2960.000
TTM5.296YOY12.299-7.002
TTM5.2965Y5.999-0.703
5Y5.99910Y4.285+1.714
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.3621.905+0.457
MRQ5.2962.111+3.185
TTM5.2962.095+3.201
YOY12.2992.836+9.463
5Y5.9993.443+2.556
10Y4.2853.794+0.491
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Nykode Therapeutics ASA compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.252-1.2520%0.514-344%0.909-238%0.758-265%
Book Value Per Share--5.3095.3090%6.562-19%3.876+37%2.990+78%
Current Ratio--5.4355.4350%8.157-33%10.035-46%12.005-55%
Debt To Asset Ratio--0.2910.2910%0.269+8%0.208+40%0.166+75%
Debt To Equity Ratio--0.4110.4110%0.368+11%0.274+50%0.214+92%
Dividend Per Share----0%-0%-0%-0%
Eps---1.445-1.4450%-0.318-78%0.136-1162%-0.062-96%
Free Cash Flow Per Share---0.790-0.7900%0.010-8328%0.945-184%0.945-184%
Free Cash Flow To Equity Per Share---0.778-0.7780%0.701-211%1.261-162%1.261-162%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--8.407--------
Intrinsic Value_10Y_min--7.511--------
Intrinsic Value_1Y_max--1.574--------
Intrinsic Value_1Y_min--1.529--------
Intrinsic Value_3Y_max--4.172--------
Intrinsic Value_3Y_min--3.950--------
Intrinsic Value_5Y_max--6.097--------
Intrinsic Value_5Y_min--5.644--------
Market Cap4094886639.360-124%9182473070.0809182473070.0800%26352260908.800-65%12004483463.808-24%8574631045.577+7%
Net Profit Margin---5.963-5.9630%-0.277-95%-149.544+2408%-125.570+2006%
Operating Margin---7.416-7.4160%-0.317-96%-969.965+12980%-782.510+10452%
Operating Ratio--8.4718.4710%1.317+543%148.245-94%105.890-92%
Pb Ratio2.362-124%5.2965.2960%12.299-57%5.999-12%4.285+24%
Pe Ratio-8.676+55%-19.456-19.4560%-253.517+1203%-51.633+165%-36.881+90%
Price Per Share12.540-124%28.12028.1200%80.700-65%36.762-24%26.259+7%
Price To Free Cash Flow Ratio-15.870+55%-35.588-35.5880%8403.566-100%1676.057-102%1197.184-103%
Price To Total Gains Ratio-10.013+55%-22.454-22.4540%156.962-114%49.725-145%49.725-145%
Quick Ratio--5.3455.3450%8.427-37%9.431-43%7.573-29%
Return On Assets---0.193-0.1930%-0.035-82%-0.081-58%-0.088-55%
Return On Equity---0.272-0.2720%-0.049-82%-0.087-68%-0.094-65%
Total Gains Per Share---1.252-1.2520%0.514-344%0.909-238%0.758-265%
Usd Book Value--157077355.944157077355.9440%194128356.671-19%114672080.960+37%88459479.959+78%
Usd Book Value Change Per Share---0.113-0.1130%0.047-344%0.082-238%0.069-265%
Usd Book Value Per Share--0.4810.4810%0.594-19%0.351+37%0.271+78%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.131-0.1310%-0.029-78%0.012-1162%-0.006-96%
Usd Free Cash Flow---23376833.571-23376833.5710%284107.358-8328%27960310.293-184%19971650.209-217%
Usd Free Cash Flow Per Share---0.072-0.0720%0.001-8328%0.086-184%0.086-184%
Usd Free Cash Flow To Equity Per Share---0.070-0.0700%0.063-211%0.114-162%0.114-162%
Usd Market Cap370996729.526-124%831932060.149831932060.1490%2387514838.337-65%1087606201.821-24%776861572.729+7%
Usd Price Per Share1.136-124%2.5482.5480%7.311-65%3.331-24%2.379+7%
Usd Profit---42759157.709-42759157.7090%-9416558.302-78%15370394.521-378%10250590.464-517%
Usd Revenue--7170709.6477170709.6470%33975838.693-79%51259526.656-86%36625115.832-80%
Usd Total Gains Per Share---0.113-0.1130%0.047-344%0.082-238%0.069-265%
 EOD+3 -5MRQTTM+0 -0YOY+3 -305Y+9 -2410Y+10 -23

3.2. Fundamental Score

Let's check the fundamental score of Nykode Therapeutics ASA based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-8.676
Price to Book Ratio (EOD)Between0-12.362
Net Profit Margin (MRQ)Greater than0-5.963
Operating Margin (MRQ)Greater than0-7.416
Quick Ratio (MRQ)Greater than15.345
Current Ratio (MRQ)Greater than15.435
Debt to Asset Ratio (MRQ)Less than10.291
Debt to Equity Ratio (MRQ)Less than10.411
Return on Equity (MRQ)Greater than0.15-0.272
Return on Assets (MRQ)Greater than0.05-0.193
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Nykode Therapeutics ASA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5030.975
Ma 20Greater thanMa 5013.988
Ma 50Greater thanMa 10015.625
Ma 100Greater thanMa 20017.225
OpenGreater thanClose12.760
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets221,477
Total Liabilities64,459
Total Stockholder Equity157,018
 As reported
Total Liabilities 64,459
Total Stockholder Equity+ 157,018
Total Assets = 221,477

Assets

Total Assets221,477
Total Current Assets211,873
Long-term Assets9,604
Total Current Assets
Cash And Cash Equivalents 205,843
Net Receivables 2,544
Other Current Assets 543
Total Current Assets  (as reported)211,873
Total Current Assets  (calculated)208,930
+/- 2,943
Long-term Assets
Property Plant Equipment 9,526
Intangible Assets 32
Other Assets 46
Long-term Assets  (as reported)9,604
Long-term Assets  (calculated)9,604
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities38,985
Long-term Liabilities25,473
Total Stockholder Equity157,018
Total Current Liabilities
Accounts payable 2,313
Other Current Liabilities 27,944
Total Current Liabilities  (as reported)38,985
Total Current Liabilities  (calculated)30,257
+/- 8,728
Long-term Liabilities
Long term Debt Total 4,365
Other Liabilities 21,109
Long-term Liabilities  (as reported)25,473
Long-term Liabilities  (calculated)25,474
+/- 1
Total Stockholder Equity
Common Stock338
Retained Earnings 64,713
Capital Surplus 83,318
Other Stockholders Equity 8,649
Total Stockholder Equity (as reported)157,018
Total Stockholder Equity (calculated)157,018
+/-0
Other
Capital Stock338
Cash and Short Term Investments 205,843
Common Stock Shares Outstanding 294,696
Liabilities and Stockholders Equity 221,477
Net Invested Capital 157,019
Net Tangible Assets 156,986
Net Working Capital 172,888
Property Plant and Equipment Gross 12,538



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
> Total Assets 
24,928
23,870
17,066
33,386
230,028
265,556
221,477
221,477265,556230,02833,38617,06623,87024,928
   > Total Current Assets 
24,889
214,031
152,854
33,174
229,032
255,858
211,873
211,873255,858229,03233,174152,854214,03124,889
       Cash And Cash Equivalents 
2,873
3,803
3,625
-1
183,376
216,231
205,843
205,843216,231183,376-13,6253,8032,873
       Short-term Investments 
0
18,564
12,477
21,681
24,944
12,169
0
012,16924,94421,68112,47718,5640
       Net Receivables 
0
6,958
8,306
1,262
3,750
23,750
2,544
2,54423,7503,7501,2628,3066,9580
       Other Current Assets 
0
700
946
1
-1
472
543
543472-119467000
   > Long-term Assets 
0
0
287
111
996
9,698
9,604
9,6049,69899611128700
       Property Plant Equipment 
10
89
110
73
407
9,165
9,526
9,5269,165407731108910
       Intangible Assets 
30
33
33
34
32
32
32
32323234333330
       Other Assets 
0
46
74
5
556
501
46
46501556574460
> Total Liabilities 
1,742
1,217
1,476
5,755
51,178
71,501
64,459
64,45971,50151,1785,7551,4761,2171,742
   > Total Current Liabilities 
1,742
10,937
13,266
4,318
13,181
31,367
38,985
38,98531,36713,1814,31813,26610,9371,742
       Accounts payable 
0
6,084
5,521
1,522
1,612
2,746
2,313
2,3132,7461,6121,5225,5216,0840
       Other Current Liabilities 
0
3,992
6,528
269
1,613
17,976
27,944
27,94417,9761,6132696,5283,9920
   > Long-term Liabilities 
0
0
1,163
0
37,997
40,134
25,473
25,47340,13437,99701,16300
       Long term Debt Total 
0
0
0
33
8
5,820
4,365
4,3655,820833000
       Other Liabilities 
0
0
0
1,404
37,989
34,314
21,109
21,10934,31437,9891,404000
       Deferred Long Term Liability 
0
0
0
0
551
478
0
04785510000
> Total Stockholder Equity
23,186
22,652
15,590
27,631
178,850
194,055
157,018
157,018194,055178,85027,63115,59022,65223,186
   Common Stock
20,830
2,417
2,424
316
327
333
338
3383333273162,4242,41720,830
   Retained Earnings 
-5,437
-86,333
-150,126
-32,905
116,869
107,455
64,713
64,713107,455116,869-32,905-150,126-86,333-5,437
   Capital Surplus 
7,793
31,992
32,029
59,133
60,348
81,526
83,318
83,31881,52660,34859,13332,02931,9927,793
   Treasury Stock0000000
   Other Stockholders Equity 
0
0
-1
1,087
1,306
4,741
8,649
8,6494,7411,3061,087-100



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue13,576
Cost of Revenue--
Gross Profit-13,576
 
Operating Income (+$)
Gross Profit-
Operating Expense-69,288
Operating Income-55,712-69,288
 
Operating Expense (+$)
Research Development-
Selling General Administrative-
Selling And Marketing Expenses-
Operating Expense69,2880
 
Net Interest Income (+$)
Interest Income7,022
Interest Expense-2,630
Other Finance Cost-5,123
Net Interest Income9,515
 
Pretax Income (+$)
Operating Income-55,712
Net Interest Income9,515
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-46,936-55,712
EBIT - interestExpense = -2,630
-42,022
-39,392
Interest Expense2,630
Earnings Before Interest and Taxes (EBIT)--44,306
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-46,936
Tax Provision--4,914
Net Income From Continuing Ops-42,022-42,022
Net Income-42,022
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--9,515
 

Technical Analysis of Nykode
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Nykode. The general trend of Nykode is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Nykode's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Nykode Therapeutics ASA.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 15.64 < 16.28 < 16.78.

The bearish price targets are: .

Tweet this
Nykode Therapeutics ASA Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Nykode Therapeutics ASA. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Nykode Therapeutics ASA Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Nykode Therapeutics ASA. The current macd is -0.76569963.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Nykode price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Nykode. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Nykode price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Nykode Therapeutics ASA Daily Moving Average Convergence/Divergence (MACD) ChartNykode Therapeutics ASA Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Nykode Therapeutics ASA. The current adx is 27.95.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Nykode shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Nykode Therapeutics ASA Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Nykode Therapeutics ASA. The current sar is 14.04.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Nykode Therapeutics ASA Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Nykode Therapeutics ASA. The current rsi is 30.98. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Nykode Therapeutics ASA Daily Relative Strength Index (RSI) ChartNykode Therapeutics ASA Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Nykode Therapeutics ASA. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Nykode price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Nykode Therapeutics ASA Daily Stochastic Oscillator ChartNykode Therapeutics ASA Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Nykode Therapeutics ASA. The current cci is -155.61422034.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Nykode Therapeutics ASA Daily Commodity Channel Index (CCI) ChartNykode Therapeutics ASA Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Nykode Therapeutics ASA. The current cmo is -47.38909051.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Nykode Therapeutics ASA Daily Chande Momentum Oscillator (CMO) ChartNykode Therapeutics ASA Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Nykode Therapeutics ASA. The current willr is -94.63087248.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Nykode Therapeutics ASA Daily Williams %R ChartNykode Therapeutics ASA Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Nykode Therapeutics ASA.

Nykode Therapeutics ASA Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Nykode Therapeutics ASA. The current atr is 0.64418758.

Nykode Therapeutics ASA Daily Average True Range (ATR) ChartNykode Therapeutics ASA Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Nykode Therapeutics ASA. The current obv is -60,331,002.

Nykode Therapeutics ASA Daily On-Balance Volume (OBV) ChartNykode Therapeutics ASA Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Nykode Therapeutics ASA. The current mfi is 30.70.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Nykode Therapeutics ASA Daily Money Flow Index (MFI) ChartNykode Therapeutics ASA Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Nykode Therapeutics ASA.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-11-28WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-28BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-03CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-29CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-08RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Nykode Therapeutics ASA Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Nykode Therapeutics ASA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5030.975
Ma 20Greater thanMa 5013.988
Ma 50Greater thanMa 10015.625
Ma 100Greater thanMa 20017.225
OpenGreater thanClose12.760
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Nykode with someone you think should read this too:
  • Are you bullish or bearish on Nykode? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Nykode? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Nykode Therapeutics ASA

I send you an email if I find something interesting about Nykode Therapeutics ASA.


Comments

How you think about this?

Leave a comment

Stay informed about Nykode Therapeutics ASA.

Receive notifications about Nykode Therapeutics ASA in your mailbox!